Results 151 to 160 of about 37,430 (216)

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma. [PDF]

Br J Haematol
Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Ahmed S, Deeba RE, Tang G, Aljawai Y, Lee HC, Patel KK, Gaballa MR, Kebriaei P, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O.   +22 more
europepmc   +1 more source

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN). [PDF]

Am J Hematol
Ludwig H, Terpos E, Gay F, van de Donk NWCJ, Bernhard S, Engelhardt M, Cook G, Schjesvold F, Einsele H, Jackson G, Pawlyn C, Mateos MV, Zweegman S, Schreder M, Beksaç M, Driessen C, Ocio EM, Popat R, Rasche L, Touzeau C, Musto P, Broijl A, Dimopoulos M, Hajek R, Boccadoro M, Sonneveld P.   +25 more
europepmc   +1 more source

Myeloid-derived suppressor cells in multiple myeloma: mechanistic insights and therapeutic implications. [PDF]

Front Immunol
Wen J, Zhou Q, Yue J, Zhang Y, Zheng Y, Xu F.   +5 more
europepmc   +1 more source

Paraneoplastic pemphigus associated with follicular lymphoma and myasthenia gravis: Efficacy of a lenalidomide-rituximab-corticosteroid regimen. [PDF]

JAAD Case Rep
Shen Y, Wang Q, Xu C, Zhu W, Zhu H, Pan M, Wang J.   +6 more
europepmc   +1 more source

Correction: Multiple myeloma in the real world settings: prognostic significance of 1q21 chromosomal abnormalities - single center experience. [PDF]

Front Oncol
Sretenovic A, Mitrovic M, Bukumiric Z, Vukosavljevic N, Kecman N, Jovanovic J, Fekete MD, Zaric E, Bila J.   +8 more
europepmc   +1 more source

Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. [PDF]

Future Oncol
Tan CR, Gordan L, Richter J, DiLeo R, Mewawalla P, Larson S, Davies F, Oveisi D, Gupta-Werner N, Medhekar R, Yin X, Cortoos A, Armoon M, Thompson-Leduc P, Rahman A, Tardif-Samson A, Vanden Eynde C, Reitan J, Milkovich G, Bubalo J, Forman A, Bryan B, Sborov D, Kaila S, Usmani S.   +24 more
europepmc   +1 more source

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial. [PDF]

Nat Med
Raab MS, Weinhold N, Kortüm KM, Krönke J, Fenk R, Weisel K, Podola L, Bertsch U, Brobeil A, Mersi J, Huhn S, Arlinghaus R, Hundemer M, Bohl SR, Mai EK, Schub N, Waldschmidt J, Bassermann F, Müller-Tidow C, Heuck C, Sakabedoyan C, Khan J, Ershova E, Koster BD, Engelhardt M, Hänel M, Salwender H, Teipel R, Goldschmidt H, Einsele H, Rasche L, GMMG-HD10/DSMM-XX (MajesTEC-5) investigators.   +31 more
europepmc   +1 more source

First-Line treatment for transplant-ineligible newly diagnosed multiple myeloma: a Bayesian network meta-analysis of efficacy, safety, and high-risk subgroups. [PDF]

Front Immunol
Zhong D, Cheng H, Zeng L, Tian C, Liang C, Wei H, Xu M, Pang M, Ke Q, Tan X, Cen H, Liao C.   +11 more
europepmc   +1 more source